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Policy approaches to improve availability
and affordability of medicines in Mexico –
an example of a middle income country
Daniela Moye-Holz*, Jitse P van Dijk, Sijmen A. Reijneveld and Hans V. Hogerzeil
Abstract
Background: The World Health Organization recommends establishing and implementing a national
pharmaceutical policy (NPP) to guarantee effective and equitable access to medicines. Mexico has implemented
several policy approaches to regulate the pharmaceutical sector, but it has no formal NPP. This article describes the
approach that the Mexican government has taken to improve availability and affordability of essential medicines.
Methods: Descriptive policy analysis of public pharmaceutical policy proposals and health action plans on the basis
of publicly available data and health progress reports, with a focus on availability and affordability of medicines.
Results: The government has implemented pooled procurement, price negotiations, and an information platform
in the public sector to improve affordability and availability. The government mainly reports on the savings that
these strategies have generated in the public expenditure but their full impact on availability and affordability has
not been assessed.
Conclusions: To increase availability and affordability of medicines in the public sector, the Mexican government
has resorted on isolated strategies. In addition to efficient procurement, price negotiations and price information,
other policy components and pricing interventions are needed. All these strategies should be included in a
comprehensive NPP.
Keywords: Medicines, Availability, Affordability, Policy, Mexico, Middle-income country, Price negotiations, Pooled
procurement
Background
Medicines are essential for the realization of the right to
health [1]. They are one of the most effective tools to
control, treat and cure diseases. Access to medicines is
also one of the most sensitive indicators of the perform-
ance of a functional health system [2]. Barriers that pre-
vent equitable and effective access to medicines limit the
capacity of the system to address health issues [3]. To
guarantee equitable access to medicines, the World
Health Organization (WHO) has suggested the develop-
ment and implementation of a national pharmaceutical
policy (NPP). An NPP is “a commitment to a goal and a
guide of action” for the pharmaceutical segment in the
public and private sectors. Its purpose is to guarantee
the availability and equitable access to medicines of as-
sured quality, and their rational use by the population,
by addressing all relevant aspects of pharmaceuticals [1].
A comprehensive NPP should address all aspects related
to pharmaceuticals and medicines access, such as the le-
gislative and regulatory framework, the selection of es-
sential medicines as offered, the method of supply to
ensure availability, rational use, affordability, the finan-
cial strategies for the optimal use of resources and the
regulation of the market, the monitoring and evaluation,
research and development, among others [4]. An NPP
should also address potentially conflicting objectives or
stakeholder interests, and should outlay the stakeholders’
roles and responsibilities [1].
Over the years, many low- and middle-income coun-
tries (LMIC) have implemented policies aimed at
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improving access to medicines [5]. However, in four
WHO regions of the world (Africa, Eastern Mediterra-
nean, Americas and Western Pacific), less than a third of
the countries have a current and updated NPP [6]. In
the Americas, 8 out of 31 countries surveyed in 2007 by
WHO reported having one: Mexico, Brazil, Chile, Peru,
Bolivia, Paraguay, Colombia and Venezuela [6, 7]. In
many countries of Latin America (LATAM), the
decentralization of health services has led to problems
related to access to health care, including medicines.
Even when many LATAM countries have implemented
health reforms over the last years, comprehensive
pharmaceutical policies have been left out [8].
Accessibility and affordability of medicines present im-
portant opportunities for improvement in many middle
income countries (MIC) – including Mexico. There is
some data on the availability of medicines to the popula-
tion, and limited information on the affordability of
these in the public and private sectors [9–12]. Studies in
the late 90’s showed that about half of essential medi-
cines were available in public healthcare facilities [13]
reporting that lack of financial resources, inefficient pro-
curement planning and distribution contributed to the
unavailability of medicines [12, 13]. Other studies
showed how prices of branded medicines in Mexico
exceeded those in international markets [11].
Contradictory to a WHO report mentioning the avail-
ability of an NPP [7], Mexico does not have a single and
concrete policy [8, 14]. In 2005 the Ministry of Health
(MoH) created the background document ‘Towards an in-
tegral pharmaceutical policy for Mexico’ (Hacia una
Política Farmacéutica Integral para México - HPFIM)
intended to serve as a basis for an NPP but this document
was never endorsed by the government [12, 15, 16]. Yet,
even in the absence of an official NPP, some relevant pol-
icy instruments have been implemented addressing medi-
cine accessibility.
Expenditure on health care constitutes 6.2% of the
Gross Domestic Product (GDP) in Mexico [17]. Pharma-
ceutical expenditure represents 1.7% of the GDP [17, 18]
and 26% [19] of the total overall health expenditure. In
the public sector in Mexico, access to medicines is real-
ized through the different social security schemes that
cover formal employees, and the people’s health insur-
ance (SPS) and the Ministry of Health (MoH) that dir-
ectly provide access to medicines and health care to
those without social security (mainly poor parts of the
population and people in the informal sector) [20]. The
federal government establishes a national formulary, and
each public health provider and institution can establish
its own formulary based on the national one. These in-
stitutional formularies dictate the medicines that should
be accessible in the institution free of charge to the
beneficiaries. Furthermore, since the health reform in
2000 that introduced the SPS in Mexico, the government
has implemented policies and reforms to guarantee
equitable access to health care [21]. This reform also in-
troduced the decentralization of public procurement [8].
This allows social security and other public health institu-
tions to procure their own medicines for their facilities,
and SPS to reimburse health providers based on its cata-
logue of interventions and medicines that it covers. By
doing so the government has tried to contain rising public
spending on pharmaceuticals while guaranteeing their
availability and accessibility [12] through different policies
and strategies. The variation in coverage, medicines formu-
laries and management of each public health institution
and the introduction of the SPS has led to a fragmented
system with differences in access to medicines and in the
efficient use of resources among institutions [20].
The present study aims to describe the approach that
the Mexican government has taken to improve accessi-
bility in the last decade. A descriptive policy analysis was
conducted by identifying and describing the strategies
and actions proposed and implemented by the govern-
ment aimed at improving availability and affordability of
pharmaceuticals.
Methods
This descriptive policy analysis follows an inductive re-
search approach, with government reports and grey and
peer-reviewed literature as data sources. The study was
conducted in three stages, as shown in Fig. 1.
First, relevant government pharmaceutical policies and
strategies from 2005 to 2013 were identified and com-
pared. Objectives, strategies and proposed lines of action
on accessibility and affordability were identified. Three
focus areas were selected: procurement, pricing, and in-
formation on medicines. Second, MoH’s yearly progress
reports from 2007 until 2015 were studied, to collect
data on affordability and accessibility of medicines.
These data were compared with the policies and strat-
egies previously identified. Thirdly, a literature review
was conducted with the following keywords: Mexico,
medicines, access to medicines, access to treatments,
medicines policies, pharmaceutical policies, availability
and affordability of medicines, medicines prices, price
negotiations, Coordinating Commission for the Negoti-
ation of Prices of Medicines (Comisión Coordinadora
para la Negociación de Precios de Medicamentos -
CCNPMIS), procurement of medicines, national formu-
lary, essential medicines list, basic scheme and catalogue
for medicines and health devices (CBMCIS), pooled pro-
curement, supply of medicines. The literature search
was conducted in Google and Google Scholar, the web-
sites of the MoH, Pan American Health Organization
(WHO/PAHO), National Institute of Public Health in
Mexico (INSP), BVS (virtual library of Mexico in
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Health), OECD, Fundación para la Salud (FUNSALUD),
PubMed, and grey literature from various sources.
The following inclusion criteria were used: publication
date between 2005 and 2016; the document referred to
Mexico; the document presented data and/or opinions
focusing on medicines affordability, accessibility and/or
availability of medicines, and medicines policies.
Approximately 40 documents were identified, of which
26 were used.
Data analysis included verifying whether progress on
the strategies reported by the government responded to
the strategies and lines of action proposed. Grey litera-
ture served to support this comparison and to provide
further input.
Results
Key pharmaceutical policy documents and the
development of an NPP
In 2005 the HPFIM document was issued to serve as a
basis for a national pharmaceutical policy. The next gov-
ernment (2007-2012) adopted some aspects of this docu-
ment related to medicines access in its health action
plan (PROSESA) for 2007-2012 [14]. In its action 3.6,
the government committed to developing an NPP that
promotes the efficient and timely supply of medicines.
In 2007 the representatives of the National Executive
and Legislative Powers, together with relevant stake-
holders, signed the “Commitment to guarantee the suffi-
ciency, availability and fair prices of medicines” [22]. The
commitment outlined 14 lines of action. Some were used
in successive governmental health plans [23] but no for-
mal and comprehensive policy was published and
implemented.
In 2011, the civil association FUNSALUD analyzed the
pharmaceutical sector in Mexico, and provided policy
proposals with more specific strategies and lines of ac-
tion [24]. This document also remained a proposal. The
current government’s health action plan for 2013-2018
[25] set its own strategies and lines of action. Figure 2
presents a timeline with the policy documents, strategies
and proposals developed during the time frame of 2005-
2015 that aimed to develop an NPP.
The policy documents issued in 2005 and 2011
remained as proposals and no formal and single NPP,
addressing all pharmaceutical access aspects in a com-
prehensive manner, was developed. However, we identi-
fied isolated policies and strategies addressing several
aspects of medicines. We further describe the policies is-
sued in the last years that have aimed to improve avail-
ability and affordability.
Availability and procurement of medicines
HPFIM and both health plans acknowledge the need for
strategies to improve medicine availability in the public
sector. One of the main strategies promoted is pooled or
consolidated procurement of multi-source medicines,
with the goal of maintaining efficiency of public procure-
ment and also monitoring the level of compliance with
generic policies.
In 2006, the Mexican Institute of Social Security (Insti-
tuto Mexicano del Seguro Social - IMSS) started consoli-
dating the procurement of multi-source medicines,
setting maximum reference prices [26, 27] for public
procurement. IMSS’s main procurement objective has
been low prices [27, 28]. This approach has brought
considerable savings but some observers state that it
“has been prone to low quality and non-compliance of
the providers” [26, 28]. In 2011, the OECD reported that
centralized medicines procurement had a 30% contract
non-compliance rate on quality and delivery of goods
from providers in some isolated regions in the country
[26]. Since 2012, other social security health institutions
and public hospitals have joined the consolidated pro-
curement led by IMSS [29]; some health ministries of
states and federal hospitals are also joining gradually.
During the annual procurement rounds of 2013-2015
the government reported accumulated savings of
Fig. 1 Flow chart of the documents reviewed for the analysis of policies regarding medicines
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$10,863 million Mexican pesos (MXP) (US$776.78 mil-
lion) [30–32].
The government defines availability as “the percentage
of patients that got their medicine prescriptions com-
pletely filled in the public sector” and reported a slight
increase from 78% in 2003 to 80.1% in 2010 [33]. How-
ever, the probability of obtaining medicines still varies
depending on the health institution and states [34–36].
According to the 2012 National Health and Nutrition
Survey [37] 92% of out-patient users received their pre-
scribed medicines. Of these patients 65.2% received their
medicines at the pharmacy of their health care unit the
day of their doctor’s appointment, while the rest had to
go to another facility or come back another day(s) to fill
their prescriptions. The survey reported that 66-86.1% of
the patients using social security services got their pre-
scriptions completely filled. As for state health services
(Servicios Estatales de Salud -SESA), 63.7% of patients
received their prescribed medicines [37]. Patients with
social security are more likely to get their prescriptions
filled than those in SESAs, which are affiliates of the
People’s Health Insurance (Seguro Popular de Salud,
SPS) and patients without any health insurance (non-
SPS users) [34, 38, 39]. These data were reported before
2012 when the pooled procurement was extended. Since
then no data have been published on actual availability
of medicines and on the impact of the pooled procure-
ment strategy on access to medicines in the public
sector.
Prices of medicines
According to HPFIM, medicine prices in Mexico are one
of the highest in LATAM countries [10, 40–43].
Chaumont et al. reported that for several originator anti-
retrovirals, like lopinavir + ritonavir, atazanavir, and
tenofovir, prices in Mexico are higher than other
middle-income countries and sometimes even higher
than high-income countries [44]. In a survey of afford-
ability and availability of medicines in Mexico City the
prices of several generic and originator brand products
were 2 to 5 times higher than in other LATAM coun-
tries [10]. According to Danzon and Furukawa [45, 46]
who compared medicine prices among several countries,
“when prices are adjusted according to income,
Mexicans are paying higher prices than people in other
countries” [10, 15, 46, 47].
Since 2004, following the agreement between the
Mexican government and the pharmaceutical industry,
the mechanism used to contain medicine prices has
been limited to patented medicines. The prices of
multi-source medicines are no longer regulated and
follow free market competition [15]. In the current
pricing scheme, each pharmaceutical company sets
the maximum retail price (MRP) of its products. Par-
ticipation to the scheme is voluntary [10, 15, 40, 47].
If companies fail to adhere to the scheme, they could
be subject to other price control mechanisms when a
lack of effective competition exists [15]. To define the
MRP, a company takes the average price of at least 6
countries, weighed from the actual sales volume, for
the last 3 months of the date of the proposed MRP
registration [15]. The price in Mexico, together with
the price-setting report and how the company will
calculate future price increases, is reported to the
Ministry of Economics (MoE) and must be printed on
the package [15].
Fig. 2 Timeline of proposals and actions to establish a National Pharmaceutical Policy and strategies to improve affordability and availability of
medicines: 2005 to 2015
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In 2015 the Senate submitted a new initiative re-
garding medicine prices [40]. This project included a
reform to the General Health Law – an amendment
of articles 17bis and 31, and the inclusion of articles
31 bis and 233 bis. The reform to Article 31 pro-
posed that the MoE should fix the MRPs of medi-
cines, after hearing the MoH. Article 31bis proposed
to set the MRP on the basis of external reference
pricing (ERP). Article 17bis introduced surveillance
on the compliance of articles 31 and 31bis. Article
233bis introduced an information system for medi-
cines prices and availability in pharmacies, to be in-
cluded on the national regulatory agency website.
However, these proposed reforms were not accepted
in the law [48].
In 2008 a coordinating commission for price nego-
tiations (CCNPMIS) was created to end the variance
in prices paid for the same product in the public
sector, to reduce expenditure on single-source medi-
cines, and to increase their accessibility. It negotiates
public procurement prices of single-source products
included in the national formulary [49]. The negotia-
tions take place on a yearly basis. The negotiating
criteria include the therapeutic benefits with respect
to other alternatives, and the estimated consumption
volume [50].
From 2008 to 2015 the number of participating
companies and the number of negotiated products
has increased, as reported in the annual government
reports (Fig. 3). The CCNPMIS has contributed to
standardizing the prices for patented medicines in the
public health sector [51]. Within its first 5 years of
operation, it obtained important savings and has pre-
vented price increases [42, 52]. Over the seven nego-
tiating rounds, the authorities estimate savings close
to 18,000 million MXP (US$1417million) [30] on the
expenditure of medicines [53].
Any price reduction achieved by the CCNPMIS
can be considered as a success [54]. Yet the com-
mission also faces significant challenges, such as poor
coordination and lack of communication among the insti-
tutions with respect to the timely preparation of back-
ground materials required for the negotiations. There is a
shortage of staff members with the necessary technical ex-
pertise [29, 52], poor management of the annual negoti-
ation process, lack of political support, and lack of explicit
indicators for assessing its performance [52].
Improving availability and prices of medicines through
information systems
In 2011 the government implemented the Sectorial
Centre of Web Management of Medicines Information
(CesMed) to further improve procurement practices and
prevent large variations in prices. CesMed aims to pro-
vide states and public health institutions information
about medicines included in the national formulary,
comparative prices and volumes, and the best procure-
ment practices. By 2015 CesMed had captured informa-
tion from approximately 70 institutions. However it is
not mandatory for institutions to report and share infor-
mation. This has limited the collection of timely and
complete information. The system does not operate in
real time, further limiting its use for decision making.
Information management continues to be segmented
and each institution manages their information inde-
pendently [55, 56].
Discussion
We analyzed the strategies the Mexican government
has used to improve availability and affordability of
medicines. Since 2005 these efforts have focused on
pooled procurement of multi-source medicines, cen-
tral price negotiations of patented medicines, and the
creation of an electronic information platform in the
Fig. 3 Number of companies participating in the Coordinating Commission for the Negotiation of Prices of Medicines Negotiation process and
number of products negotiated
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public sector. The government has limited the report-
ing on the impact of these initiatives to overall sav-
ings on expenditure without much supporting
evidence.
We started by reviewing policy documents and pro-
posals that aimed at the development of an NPP. Sev-
eral authors [8, 57–59] have analyzed the
development of pharmaceutical policies by various
countries, reporting on the complexity of such
process and how this development is specific accord-
ing to each country’s settings and circumstances.
Hobert et al. reported that LMIC are more likely to
develop an NPP, as a comprehensive policy is more
inclined to address pharmaceutical problems and im-
prove access to medicines, than single policy compo-
nents [57] as in the Mexican case. For many LMIC
pharmaceutical policies have come as a part of an
overall health reform [58]. These policies have mostly
aimed at a more efficient and rational use of re-
sources as well as reaching equity [8, 58, 59], while
accommodating stakeholders concerns and roles on
access to medicines [8]. Thus, the WHO has pro-
moted the implementation of an NPP and has pro-
vided support to LMIC to develop their own [1]. Up
to date no single and comprehensive NPP has been
developed in Mexico. Instead, it has been developed
in isolated components, found in several laws, policies
and procedures [57].
Availability of medicines
We found that pooled procurement has generated es-
timated savings of about 10% of the pharmaceutical
expenditure. However, improvement in availability of
medicines has not been assessed. Experiences with
PAHO’s Revolving Fund [60, 61], and centralized pro-
curement mechanisms used in Brazil [62], Argentina,
Uruguay, and in Chile [63, 64] have shown that by
consolidating product requirements and increasing
purchase volumes, purchasers can benefit from econ-
omies of scale leading to lower prices and increasing
procurement efficiency [61, 65]. Thus, the extended
use of pooled procurement has indeed the potential
to promote efficiency and reduce variations in medi-
cines prices within the Mexican public sector. In
order to assure the availability of medicines in public
health care facilities in Mexico, a more comprehen-
sive assessment of the procurement process is needed,
considering the product specifications, contractual
conditions of delivery, and sanctions in case of non-
compliance. Suppliers invited to tender should first be
pre-qualified [66] to ensure the quality of their goods
and the reliability of the delivery process. It is also
important to monitor the impact of the pooled pro-
curement on the ultimate availability of medicines, in
comparison to previous years, and to monitor sup-
plier performance.
Affordability of medicines
We found that for single source medicines in the na-
tional formulary, the government has introduced price
negotiations [56]. This follows examples in other
countries, such as Canada and Western Europe,
where monopsony purchase and bargaining powers
have kept prices low [66]. Hospitals in Colombia
carry out joint negotiations [67] and Brazil has in-
cluded in its law provisions on patents and intellec-
tual property that have helped to improve its
negotiating power [68–70]. In Mexico, progress re-
ports on the impact of the negotiations have focused
on discounts and savings achieved, which can be esti-
mated at around 7% of pharmaceutical expenditure.
However, it is not clear whether the negotiated final
prices have been respected during procurement pro-
cedures [71] and whether access to these medicines
has actually improved. Some challenges need to be
addressed to improve the role of the CCNPMIS. Its
performance needs to be assessed thoroughly using
selected indicators [52]. Political support is required
to institutionalize the commission – as already pro-
posed by FUNSALUD [24] – and to strengthen its
procedures.
Pricing regulation
In Mexico, a pricing scheme for medicines in the
private sector is in place. However, there is no evi-
dence that it is adequate [9, 15, 47] since the gov-
ernment does not establish price controls itself.
Instead, the industry establishes the maximum retail
price itself. This scheme may follow a free market
philosophy, but it is not in line with WHO recom-
mendations on price controls [72, 73] where a much
more active role of the government is recommended.
Several LATAM countries, such as Brazil and
Columbia, have implemented price regulation pol-
icies based on external reference pricing mechanisms
[62, 67, 74, 75]. Mexico should also consider moving
towards active price regulation [47], to improve the
affordability and accessibility of medicines.
Price regulation and price negotiations as individual
measures are not likely to be successful. These should
be part of a comprehensive medicine policy. For ex-
ample, the country could implement internal and ex-
ternal reference pricing for multi-source (generic and
branded generic) and single-source (often patented
originator brand) medicines. It should also encourage
the use of voluntary licenses to increase competition,
and issue compulsory licenses in case the industry is
not collaborating. Other measures can also contribute
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to better affordability, such as those related to cost-
effective prescribing and therapeutic (as opposed to
generic) substitution. A full range of possible strat-
egies to reduce prices has been described elsewhere
[73, 76–79]. Most of these measures could be incor-
porated into the Mexican legislation to improve
affordability of medicines.
Procurement and pricing information
We found that participating institutions and states
have shared valuable information and success stories
in the CesMed platform that can be helpful for other
institutions facing procurement or pricing problems.
Such platform can indeed facilitate the implementa-
tion, monitoring and assessment of procurement and
prices of medicines and of a NPP [80]. However, its
potential is currently limited as only few institutions
use it. Brazil, Colombia, Argentina and Peru have also
implemented medicines’ pricing information systems
to monitor medicines prices, with the ultimate goal to
increase transparency and improve access [64, 74, 81, 82].
These systems could serve as examples for Mexico.
In the 2011 policy proposal, FUNSALUD proposed
to monitor public prices of medicines to increase the
efficiency of public procurement and the use of re-
sources [24]. CesMed could provide such platform,
but all public health institutions should participate in
a timely manner and with a uniform report format.
Increasing access to this information should allow
purchasers to compare their own prices, obtain better
prices, and better estimate their budget requirements
[64]. More transparency on pricing also helps to re-
duce and prevent corruption.
Strengths and limitations
This study is based on reported information provided
by the government, providing a scope of the actions
that Mexico has taken towards improving access to
medicines. The main strength of this study is an ex-
tensive search for policy and governmental documents
related to availability and affordability of medicines,
in addition to the analysis of the governmental yearly
health reports. However, an official document cannot
provide judgement on availability and affordability.
No detailed data on medicines affordability and avail-
ability are publicly available to fully assess the govern-
ment’s strategies. In our research we did not try to
study actual availability and affordability on the basis
of policy documents, but to identify and describe
strategies and policies aimed to improve availability
and affordability. Our data cannot provide a compre-
hensive analysis of the policies’ outcomes and short-
comings. Moreover, the information reported by the
government may have been too positive or optimistic
on the effect of these strategies on access to medi-
cines and generated savings, without fully disclosing
their real impact on actual availability and affordabil-
ity. Thus our findings may underestimate somewhat
the current availability and affordability.
We think that explanations for the limited success
of these strategies include the lack of monitoring dur-
ing implementation and lack of adaptation of the
strategies over time to achieve the desired outcomes.
Moreover, lack of transparency, some conflicts of in-
terests of stakeholders and corruption may have af-
fected the actual outcomes of these strategies and the
development of a full NPP.
Practical implications
We found that in 2007 the government committed it-
self to establishing an official NPP [22, 23]. Some as-
pects mentioned in the policy proposals of 2005 [43]
and 2011 [24] have indeed been included in health
action plans and have been followed up. Yet, an offi-
cial and comprehensive NPP [12, 14, 16] addressing
all medicine-related aspects of a health system [1, 57]
is still lacking. In view of the many different stake-
holders and the need for a comprehensive approach
to further improve medicine availability and afford-
ability, the official development, adoption and imple-
mentation of an NPP is very much needed.
Experiences in other countries have shown that an
NPP, developed in a consultative manner with all in-
volved stakeholders, should provide a common
ground of action with the main goal of guaranteeing
access to medicines [57, 83].
The government has implemented isolated policy
components to improve availability and affordability
of medicines. Although desired outcomes have been
achieved, all these approaches have shown limitations
in their implementation. Most public health institu-
tions have joined to increase the procurement volume
and achieve savings through pooled procurement, yet
actual unavailability has been reported due to pro-
viders’ non-compliance. This issue is related to lack
of monitoring. Also for price negotiations, the gov-
ernment has not monitored the actual procurement
prices of the negotiated medicines, to truly assess the
impact of this strategy.
Further independent research is necessary to evaluate
the effect of government strategies, to identify their
strengths and weaknesses, and measure their final im-
pact on access to essential medicines. We recommend a
comprehensive examination of the procurement process;
the institutionalization of the negotiating commission;
and increase information reporting through the CesMed
platform.
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Conclusions
To increase the availability and affordability of medi-
cines in the public sector, Mexico has focused on
pooled procurement of multi-source products, price
negotiations for single-source products and collection
and dissemination of price and procurement informa-
tion. The government claims that these strategies
have provided considerable savings. The real impact
of these strategies on actual availability and affordabil-
ity has not been independently assessed. These three
strategies have been developed and implemented in
isolation, limiting their potential impact. Ample room
exists to improve the availability and affordability of
drugs in Mexico. All strategies should be included in
one comprehensive NPP aimed not only at improving
medicines accessibility and affordability, but also at
other aspects, such as medicines quality, safety and
quality use.
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